Accuray Inc. (ARAY) Total Debt to Capital

Accuray - graphic logo of issuer ARAY

Accuray Incorporated (ARAY) experienced management is successfully scaling the brand's international presence, as reflected in the price chart where the debt-to-equity ratio stands at 4.46. The company generates revenue through the sale of robotic systems and the maintenance of tumor radiation equipment. However, the business faces intense competition for government procurement and the risk of falling behind in the field of digital therapy planning.

accuray.com (ARAY): Debt to Equity Ratio from 07/04/2022 to 10/29/2026
Finished products of Accuray Incorporated

Investors must assess the balance sheet resilience of Accuray Incorporated (ARAY) against potential interest rate risks. This ratio compares total liabilities to net assets to determine the degree of financial leverage. The trend of the company's debt-to-equity ratio demonstrates the business's reliance on borrowed funds. Excessive debt load could limit the production development of CyberKnife robotic systems. The stability of this metric confirms the company's ability to scale equipment sales for oncology centers.

Competitor analysis for Accuray Incorporated

ONC (BeiGene) - Total Debt to Capital|Total Debt to Equity Ratio Halozyme Therapeutics, Inc. (HALO)|Total Debt to Capital RVMD|Total Debt to Capital Ascentage Pharma Corp (AAPG)|Debt to Equity CG Oncology, Inc. CGON|URGN: Debt to Equity Ratio|Bicara Therapeutics - Total Debt to Capital|Personalis Inc (PSNL) - Total Debt to Equity Ratio|ERAS: Total Debt to Capital|Debt to Capital Delcath Corp (DCTH)|Debt to Equity Y-mAbs Therapeutics|AURA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CADL (Candel Therapeutics)|SLS (sellaslifesciences.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital ACTU (Actuate Therapeutics, Inc)|CTOR - Total Debt to Equity Ratio|HURA: Total Debt to Equity Ratio|TARA - Total Debt to Capital|Fate Therapeutics (FATE) - Debt to Equity|Aadi Bioscience - All Debt to Shareholders' Equity Ratio|TCRX (TScan Therapeutics Inc) - Total Debt to Capital|Debt to Capital Champions Oncology Corp CSBR|Total Debt to Capital XBIT|Total Debt to Capital cel-sci.com (CVM)|Total Debt to Capital OSTX (OS Therapies)|RADX - Total Debt to Equity Ratio|Artiva - Total Debt to Capital|Adlai Nortye Ltd. (ANL) - Total Debt to Equity Ratio|VERU (Veru Inc.) - Total Debt to Equity Ratio|tempesttx.com (TPST) - Total Debt to Capital|Debt to Equity Xilio Therapeutics Inc|RENB: All Debt to Shareholders' Equity Ratio|Total Debt to Capital MURA|Total Debt to Capital kairospharma.com (KAPA)|OnKure Therapeutics - Total Debt to Equity Ratio|CytoMed Therapeutics Ltd (GDTC) - Debt to Capital|CRIS: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio APLM (Apollomics, Inc.)|THAR: Total Debt to Capital|ADVB - Total Debt to Capital Coefficient|Debt to Equity Genprex, Inc.|Debt to Equity Ratio CLDI (Calidi Bio)|Total Debt to Capital SBFM|Total Debt to Equity Ratio xeneticbio.com XBIO|Debt to Equity Salarius SLRX|Kitov Pharma (PPBT) - Debt to Capital|AONC - Debt to Equity|All Debt to Shareholders' Equity Ratio BGNE (beigene.com)|Checkpoint Therapeutics, Inc. (CKPT) - Debt to Equity|Aggregate Debt to Equity ELEV (elevationoncology.com)|Debt to Equity iCAD Inc.|Debt to Capital Ikena IKNA|Debt to Equity Notable Labs, Ltd. (NTBL)|VIRX (viracta.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital MOR (MorphoSys)|Total Debt to Capital NAYA Biosciences Inc NAYA|AAPGV: Total Debt to Equity Ratio